newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

  • RenovoRx (NASDAQ: RNXT) will host its third quarter 2025 financial results & business highlights conference call on November 13, 2025, at 4:30 p.m. ET.
  • Management will discuss RenovoCath commercialization efforts, the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, & the PanTheR Post-Marketing Registry Study on long-term safety & survival outcomes.
  • The live call is accessible via 1-877-407-4018 (U.S.) or 1-201-689-8471 (International), with a webcast at https://ir.renovorx.com/news-events/ir-calendar-events.
  • A question-and-answer session will follow the presentation, with a recording available on the Investor Relations website & a dial-in replay accessible until November 27, 2025.
  • RenovoRx is evaluating its novel drug-device combination candidate (IAG) in the Phase III trial, which received Orphan Drug Designation for pancreatic & bile duct cancer.
  • The company announced its first commercial purchase orders for RenovoCath devices in December 2024, with repeat orders initiated by high-volume National Cancer Institute-designated centers.
  • RenovoRx plans to expand revenue through direct sales or partnerships with medical device commercial partners to meet anticipated demand for its TAMP technology.